カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の遺伝子治療ウイルスベクター&プラスミドDNA市場2023年：企業・地域・タイプ・用途別分析

■ 英語タイトル：Global Gene Therapy Viral Vector and Plasmid DNA Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23SM7096）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23SM7096
■ 発行日：2023年9月
■ 調査対象地域：グローバル
■ 産業分野：医療機器＆消耗品
■ ページ数：120
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の遺伝子治療ウイルスベクター&プラスミドDNA市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

GlobalInfoResearchの最新の調査によると、世界の遺伝子治療ウイルスベクター&プラスミドDNAの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の遺伝子治療ウイルスベクター&プラスミドDNA市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 遺伝子治療ウイルスベクター&プラスミドDNAの成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

遺伝子治療ウイルスベクター&プラスミドDNA市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・ウイルスベクター、プラスミドDNA

用途別セグメント
・細胞&遺伝子治療、ワクチン開発、研究

主要な市場プレーヤー
・Lonza、Merck KGaA、Thermo Fisher Scientific、Charles River Laboratories、Catalent、WuXi AppTec、FUJIFILM、GenScript Biotech、Takara Bio、Oxford Biomedica、Novartis、Precision Biosciences、Bluebird Bio、Sartorius AG、Danaher、SIRON Biotech、VGXI、Waisman Biomanufacturing、Kaneka Eurogentec、PlasmidFactory、ATUM、Addgene、Cell and Gene Therapy Catapult、Batavia biosciences、Altogen Biosystems

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、遺伝子治療ウイルスベクター&プラスミドDNA製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な遺伝子治療ウイルスベクター&プラスミドDNAメーカーの企業概要、2019年～2022年までの遺伝子治療ウイルスベクター&プラスミドDNAの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な遺伝子治療ウイルスベクター&プラスミドDNAメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別遺伝子治療ウイルスベクター&プラスミドDNAの販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの遺伝子治療ウイルスベクター&プラスミドDNAのタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での遺伝子治療ウイルスベクター&プラスミドDNA市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および遺伝子治療ウイルスベクター&プラスミドDNAの産業チェーンを掲載しています。
・第14、15章では、遺伝子治療ウイルスベクター&プラスミドDNAの販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 遺伝子治療ウイルスベクター&プラスミドDNAの概要
– タイプ別分析（2018年vs2022年vs2029年）：ウイルスベクター、プラスミドDNA
– 用途別分析（2018年vs2022年vs2029年）：細胞&遺伝子治療、ワクチン開発、研究
– 世界の遺伝子治療ウイルスベクター&プラスミドDNA市場規模・予測
– 世界の遺伝子治療ウイルスベクター&プラスミドDNA生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Lonza、Merck KGaA、Thermo Fisher Scientific、Charles River Laboratories、Catalent、WuXi AppTec、FUJIFILM、GenScript Biotech、Takara Bio、Oxford Biomedica、Novartis、Precision Biosciences、Bluebird Bio、Sartorius AG、Danaher、SIRON Biotech、VGXI、Waisman Biomanufacturing、Kaneka Eurogentec、PlasmidFactory、ATUM、Addgene、Cell and Gene Therapy Catapult、Batavia biosciences、Altogen Biosystems
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：ウイルスベクター、プラスミドDNA
・用途別分析2018年-2029年：細胞&遺伝子治療、ワクチン開発、研究
・遺伝子治療ウイルスベクター&プラスミドDNAの北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・遺伝子治療ウイルスベクター&プラスミドDNAのヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・遺伝子治療ウイルスベクター&プラスミドDNAのアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・遺伝子治療ウイルスベクター&プラスミドDNAの南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・遺伝子治療ウイルスベクター&プラスミドDNAの中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Gene Therapy Viral Vector and Plasmid DNA
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Viral Vectors
1.3.3 Plasmid DNA
1.4 Market Analysis by Application
1.4.1 Overview: Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cell and Gene Therapy
1.4.3 Vaccine Development
1.4.4 Research
1.5 Global Gene Therapy Viral Vector and Plasmid DNA Market Size & Forecast
1.5.1 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (2018-2029)
1.5.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.1.4 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Lonza Recent Developments/Updates
2.2 Merck KGaA
2.2.1 Merck KGaA Details
2.2.2 Merck KGaA Major Business
2.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.2.4 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck KGaA Recent Developments/Updates
2.3 Thermo Fisher Scientific
2.3.1 Thermo Fisher Scientific Details
2.3.2 Thermo Fisher Scientific Major Business
2.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.3.4 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Thermo Fisher Scientific Recent Developments/Updates
2.4 Charles River Laboratories
2.4.1 Charles River Laboratories Details
2.4.2 Charles River Laboratories Major Business
2.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.4.4 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Charles River Laboratories Recent Developments/Updates
2.5 Catalent
2.5.1 Catalent Details
2.5.2 Catalent Major Business
2.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.5.4 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Catalent Recent Developments/Updates
2.6 WuXi AppTec
2.6.1 WuXi AppTec Details
2.6.2 WuXi AppTec Major Business
2.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.6.4 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 WuXi AppTec Recent Developments/Updates
2.7 FUJIFILM
2.7.1 FUJIFILM Details
2.7.2 FUJIFILM Major Business
2.7.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.7.4 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 FUJIFILM Recent Developments/Updates
2.8 GenScript Biotech
2.8.1 GenScript Biotech Details
2.8.2 GenScript Biotech Major Business
2.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.8.4 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GenScript Biotech Recent Developments/Updates
2.9 Takara Bio
2.9.1 Takara Bio Details
2.9.2 Takara Bio Major Business
2.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.9.4 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Takara Bio Recent Developments/Updates
2.10 Oxford Biomedica
2.10.1 Oxford Biomedica Details
2.10.2 Oxford Biomedica Major Business
2.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.10.4 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Oxford Biomedica Recent Developments/Updates
2.11 Novartis
2.11.1 Novartis Details
2.11.2 Novartis Major Business
2.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.11.4 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Novartis Recent Developments/Updates
2.12 Precision Biosciences
2.12.1 Precision Biosciences Details
2.12.2 Precision Biosciences Major Business
2.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.12.4 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Precision Biosciences Recent Developments/Updates
2.13 Bluebird Bio
2.13.1 Bluebird Bio Details
2.13.2 Bluebird Bio Major Business
2.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.13.4 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bluebird Bio Recent Developments/Updates
2.14 Sartorius AG
2.14.1 Sartorius AG Details
2.14.2 Sartorius AG Major Business
2.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.14.4 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Sartorius AG Recent Developments/Updates
2.15 Danaher
2.15.1 Danaher Details
2.15.2 Danaher Major Business
2.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.15.4 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Danaher Recent Developments/Updates
2.16 SIRON Biotech
2.16.1 SIRON Biotech Details
2.16.2 SIRON Biotech Major Business
2.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.16.4 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 SIRON Biotech Recent Developments/Updates
2.17 VGXI
2.17.1 VGXI Details
2.17.2 VGXI Major Business
2.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.17.4 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 VGXI Recent Developments/Updates
2.18 Waisman Biomanufacturing
2.18.1 Waisman Biomanufacturing Details
2.18.2 Waisman Biomanufacturing Major Business
2.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.18.4 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Waisman Biomanufacturing Recent Developments/Updates
2.19 Kaneka Eurogentec
2.19.1 Kaneka Eurogentec Details
2.19.2 Kaneka Eurogentec Major Business
2.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.19.4 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Kaneka Eurogentec Recent Developments/Updates
2.20 PlasmidFactory
2.20.1 PlasmidFactory Details
2.20.2 PlasmidFactory Major Business
2.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.20.4 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 PlasmidFactory Recent Developments/Updates
2.21 ATUM
2.21.1 ATUM Details
2.21.2 ATUM Major Business
2.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.21.4 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 ATUM Recent Developments/Updates
2.22 Addgene
2.22.1 Addgene Details
2.22.2 Addgene Major Business
2.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.22.4 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Addgene Recent Developments/Updates
2.23 Cell and Gene Therapy Catapult
2.23.1 Cell and Gene Therapy Catapult Details
2.23.2 Cell and Gene Therapy Catapult Major Business
2.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.23.4 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 Cell and Gene Therapy Catapult Recent Developments/Updates
2.24 Batavia biosciences
2.24.1 Batavia biosciences Details
2.24.2 Batavia biosciences Major Business
2.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.24.4 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.24.5 Batavia biosciences Recent Developments/Updates
2.25 Altogen Biosystems
2.25.1 Altogen Biosystems Details
2.25.2 Altogen Biosystems Major Business
2.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product and Services
2.25.4 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.25.5 Altogen Biosystems Recent Developments/Updates
3 Competitive Environment: Gene Therapy Viral Vector and Plasmid DNA by Manufacturer
3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Manufacturer (2018-2023)
3.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Manufacturer (2018-2023)
3.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Gene Therapy Viral Vector and Plasmid DNA by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Gene Therapy Viral Vector and Plasmid DNA Manufacturer Market Share in 2022
3.4.2 Top 6 Gene Therapy Viral Vector and Plasmid DNA Manufacturer Market Share in 2022
3.5 Gene Therapy Viral Vector and Plasmid DNA Market: Overall Company Footprint Analysis
3.5.1 Gene Therapy Viral Vector and Plasmid DNA Market: Region Footprint
3.5.2 Gene Therapy Viral Vector and Plasmid DNA Market: Company Product Type Footprint
3.5.3 Gene Therapy Viral Vector and Plasmid DNA Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Size by Region
4.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2029)
4.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2029)
4.1.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Region (2018-2029)
4.2 North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.3 Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.4 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.5 South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
4.6 Middle East and Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
5.2 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type (2018-2029)
5.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
6.2 Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application (2018-2029)
6.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Application (2018-2029)
7 North America
7.1 North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
7.2 North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
7.3 North America Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
7.3.1 North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
7.3.2 North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
8.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
8.3 Europe Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
8.3.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
8.3.2 Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Market Size by Region
9.3.1 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
10.2 South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
10.3 South America Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
10.3.1 South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
10.3.2 South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Market Size by Country
11.3.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Gene Therapy Viral Vector and Plasmid DNA Market Drivers
12.2 Gene Therapy Viral Vector and Plasmid DNA Market Restraints
12.3 Gene Therapy Viral Vector and Plasmid DNA Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Gene Therapy Viral Vector and Plasmid DNA and Key Manufacturers
13.2 Manufacturing Costs Percentage of Gene Therapy Viral Vector and Plasmid DNA
13.3 Gene Therapy Viral Vector and Plasmid DNA Production Process
13.4 Gene Therapy Viral Vector and Plasmid DNA Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Gene Therapy Viral Vector and Plasmid DNA Typical Distributors
14.3 Gene Therapy Viral Vector and Plasmid DNA Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Lonza Basic Information, Manufacturing Base and Competitors
Table 4. Lonza Major Business
Table 5. Lonza Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 6. Lonza Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Lonza Recent Developments/Updates
Table 8. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 9. Merck KGaA Major Business
Table 10. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 11. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Merck KGaA Recent Developments/Updates
Table 13. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors
Table 14. Thermo Fisher Scientific Major Business
Table 15. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 16. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Thermo Fisher Scientific Recent Developments/Updates
Table 18. Charles River Laboratories Basic Information, Manufacturing Base and Competitors
Table 19. Charles River Laboratories Major Business
Table 20. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 21. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Charles River Laboratories Recent Developments/Updates
Table 23. Catalent Basic Information, Manufacturing Base and Competitors
Table 24. Catalent Major Business
Table 25. Catalent Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 26. Catalent Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Catalent Recent Developments/Updates
Table 28. WuXi AppTec Basic Information, Manufacturing Base and Competitors
Table 29. WuXi AppTec Major Business
Table 30. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 31. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. WuXi AppTec Recent Developments/Updates
Table 33. FUJIFILM Basic Information, Manufacturing Base and Competitors
Table 34. FUJIFILM Major Business
Table 35. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 36. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. FUJIFILM Recent Developments/Updates
Table 38. GenScript Biotech Basic Information, Manufacturing Base and Competitors
Table 39. GenScript Biotech Major Business
Table 40. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 41. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. GenScript Biotech Recent Developments/Updates
Table 43. Takara Bio Basic Information, Manufacturing Base and Competitors
Table 44. Takara Bio Major Business
Table 45. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 46. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Takara Bio Recent Developments/Updates
Table 48. Oxford Biomedica Basic Information, Manufacturing Base and Competitors
Table 49. Oxford Biomedica Major Business
Table 50. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 51. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Oxford Biomedica Recent Developments/Updates
Table 53. Novartis Basic Information, Manufacturing Base and Competitors
Table 54. Novartis Major Business
Table 55. Novartis Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 56. Novartis Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Novartis Recent Developments/Updates
Table 58. Precision Biosciences Basic Information, Manufacturing Base and Competitors
Table 59. Precision Biosciences Major Business
Table 60. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 61. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Precision Biosciences Recent Developments/Updates
Table 63. Bluebird Bio Basic Information, Manufacturing Base and Competitors
Table 64. Bluebird Bio Major Business
Table 65. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 66. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Bluebird Bio Recent Developments/Updates
Table 68. Sartorius AG Basic Information, Manufacturing Base and Competitors
Table 69. Sartorius AG Major Business
Table 70. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 71. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Sartorius AG Recent Developments/Updates
Table 73. Danaher Basic Information, Manufacturing Base and Competitors
Table 74. Danaher Major Business
Table 75. Danaher Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 76. Danaher Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Danaher Recent Developments/Updates
Table 78. SIRON Biotech Basic Information, Manufacturing Base and Competitors
Table 79. SIRON Biotech Major Business
Table 80. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 81. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. SIRON Biotech Recent Developments/Updates
Table 83. VGXI Basic Information, Manufacturing Base and Competitors
Table 84. VGXI Major Business
Table 85. VGXI Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 86. VGXI Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. VGXI Recent Developments/Updates
Table 88. Waisman Biomanufacturing Basic Information, Manufacturing Base and Competitors
Table 89. Waisman Biomanufacturing Major Business
Table 90. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 91. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Waisman Biomanufacturing Recent Developments/Updates
Table 93. Kaneka Eurogentec Basic Information, Manufacturing Base and Competitors
Table 94. Kaneka Eurogentec Major Business
Table 95. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 96. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. Kaneka Eurogentec Recent Developments/Updates
Table 98. PlasmidFactory Basic Information, Manufacturing Base and Competitors
Table 99. PlasmidFactory Major Business
Table 100. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 101. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. PlasmidFactory Recent Developments/Updates
Table 103. ATUM Basic Information, Manufacturing Base and Competitors
Table 104. ATUM Major Business
Table 105. ATUM Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 106. ATUM Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. ATUM Recent Developments/Updates
Table 108. Addgene Basic Information, Manufacturing Base and Competitors
Table 109. Addgene Major Business
Table 110. Addgene Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 111. Addgene Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 112. Addgene Recent Developments/Updates
Table 113. Cell and Gene Therapy Catapult Basic Information, Manufacturing Base and Competitors
Table 114. Cell and Gene Therapy Catapult Major Business
Table 115. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 116. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 117. Cell and Gene Therapy Catapult Recent Developments/Updates
Table 118. Batavia biosciences Basic Information, Manufacturing Base and Competitors
Table 119. Batavia biosciences Major Business
Table 120. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 121. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 122. Batavia biosciences Recent Developments/Updates
Table 123. Altogen Biosystems Basic Information, Manufacturing Base and Competitors
Table 124. Altogen Biosystems Major Business
Table 125. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product and Services
Table 126. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 127. Altogen Biosystems Recent Developments/Updates
Table 128. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 129. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Manufacturer (2018-2023) & (USD Million)
Table 130. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 131. Market Position of Manufacturers in Gene Therapy Viral Vector and Plasmid DNA, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 132. Head Office and Gene Therapy Viral Vector and Plasmid DNA Production Site of Key Manufacturer
Table 133. Gene Therapy Viral Vector and Plasmid DNA Market: Company Product Type Footprint
Table 134. Gene Therapy Viral Vector and Plasmid DNA Market: Company Product Application Footprint
Table 135. Gene Therapy Viral Vector and Plasmid DNA New Market Entrants and Barriers to Market Entry
Table 136. Gene Therapy Viral Vector and Plasmid DNA Mergers, Acquisition, Agreements, and Collaborations
Table 137. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2023) & (K Units)
Table 138. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2024-2029) & (K Units)
Table 139. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2023) & (USD Million)
Table 140. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2024-2029) & (USD Million)
Table 141. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Region (2018-2023) & (US$/Unit)
Table 142. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Region (2024-2029) & (US$/Unit)
Table 143. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2023) & (K Units)
Table 144. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2024-2029) & (K Units)
Table 145. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type (2018-2023) & (USD Million)
Table 146. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type (2024-2029) & (USD Million)
Table 147. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Type (2018-2023) & (US$/Unit)
Table 148. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Type (2024-2029) & (US$/Unit)
Table 149. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2023) & (K Units)
Table 150. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2024-2029) & (K Units)
Table 151. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application (2018-2023) & (USD Million)
Table 152. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application (2024-2029) & (USD Million)
Table 153. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Application (2018-2023) & (US$/Unit)
Table 154. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Application (2024-2029) & (US$/Unit)
Table 155. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2023) & (K Units)
Table 156. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2024-2029) & (K Units)
Table 157. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2023) & (K Units)
Table 158. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2024-2029) & (K Units)
Table 159. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2023) & (K Units)
Table 160. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2024-2029) & (K Units)
Table 161. North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2023) & (USD Million)
Table 162. North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2024-2029) & (USD Million)
Table 163. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2023) & (K Units)
Table 164. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2024-2029) & (K Units)
Table 165. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2023) & (K Units)
Table 166. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2024-2029) & (K Units)
Table 167. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2023) & (K Units)
Table 168. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2024-2029) & (K Units)
Table 169. Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2023) & (USD Million)
Table 170. Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2024-2029) & (USD Million)
Table 171. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2023) & (K Units)
Table 172. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2024-2029) & (K Units)
Table 173. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2023) & (K Units)
Table 174. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2024-2029) & (K Units)
Table 175. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2023) & (K Units)
Table 176. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2024-2029) & (K Units)
Table 177. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2023) & (USD Million)
Table 178. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2024-2029) & (USD Million)
Table 179. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2023) & (K Units)
Table 180. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2024-2029) & (K Units)
Table 181. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2023) & (K Units)
Table 182. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2024-2029) & (K Units)
Table 183. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2018-2023) & (K Units)
Table 184. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Country (2024-2029) & (K Units)
Table 185. South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2018-2023) & (USD Million)
Table 186. South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Country (2024-2029) & (USD Million)
Table 187. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2018-2023) & (K Units)
Table 188. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Type (2024-2029) & (K Units)
Table 189. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2018-2023) & (K Units)
Table 190. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Application (2024-2029) & (K Units)
Table 191. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2018-2023) & (K Units)
Table 192. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity by Region (2024-2029) & (K Units)
Table 193. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2018-2023) & (USD Million)
Table 194. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Region (2024-2029) & (USD Million)
Table 195. Gene Therapy Viral Vector and Plasmid DNA Raw Material
Table 196. Key Manufacturers of Gene Therapy Viral Vector and Plasmid DNA Raw Materials
Table 197. Gene Therapy Viral Vector and Plasmid DNA Typical Distributors
Table 198. Gene Therapy Viral Vector and Plasmid DNA Typical Customers
List of Figures
Figure 1. Gene Therapy Viral Vector and Plasmid DNA Picture
Figure 2. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Type in 2022
Figure 4. Viral Vectors Examples
Figure 5. Plasmid DNA Examples
Figure 6. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Application in 2022
Figure 8. Cell and Gene Therapy Examples
Figure 9. Vaccine Development Examples
Figure 10. Research Examples
Figure 11. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Gene Therapy Viral Vector and Plasmid DNA Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Gene Therapy Viral Vector and Plasmid DNA by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Gene Therapy Viral Vector and Plasmid DNA Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Gene Therapy Viral Vector and Plasmid DNA Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Region (2018-2029)
Figure 53. China Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Gene Therapy Viral Vector and Plasmid DNA Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Gene Therapy Viral Vector and Plasmid DNA Market Drivers
Figure 74. Gene Therapy Viral Vector and Plasmid DNA Market Restraints
Figure 75. Gene Therapy Viral Vector and Plasmid DNA Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA in 2022
Figure 78. Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA
Figure 79. Gene Therapy Viral Vector and Plasmid DNA Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の貧血遺伝子検出キット市場2023年：企業・地域・タイプ・用途別分析
  • 世界の難聴遺伝子検出キット市場2023年：企業・地域・タイプ・用途別分析
  • 世界の赤色光治療ベルト市場2023年：企業・地域・タイプ・用途別分析
  • 世界のインテンスパルスレーザー治療機市場2023年：企業・地域・タイプ・用途別分析
  • 世界の埋め込み型心臓再同期療法除細動器市場2023年：企業・地域・タイプ・用途別分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23SM7096 )"世界の遺伝子治療ウイルスベクター&プラスミドDNA市場2023年：企業・地域・タイプ・用途別分析" (英文：Global Gene Therapy Viral Vector and Plasmid DNA Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。